CRAFA
PEPTIDE & COMPOUND ANALYSIS

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-0214
Issued: 2026-09-20

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

PRODUCT IDENTIFICATION

PRODUCT Melanotan II 10 mg	SKU / INTERNAL CODE CRF-2026-0214	PRESENTATION Lyophilised powder, 10 mg vial
BATCH NUMBER CRF-2026-0214	SAMPLE RECEIVED 2026-09-13	PRODUCTION DATE 2026-09-07
ANALYSIS DATE 2026-09-18	EXPIRY / RETEST DATE 2028-09-18	MOLECULAR FORMULA (REFERENCE) C50H69N15O9
MOLECULAR WEIGHT (G/MOL; REFERENCE) 1024.2	CAS (REFERENCE) 121062-08-6	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Agilent 1290	COLUMN C18 4.6×150mm	COLUMN TEMPERATURE 35°C
MOBILE PHASE A 0.1% TFA H2O	MOBILE PHASE B ACN	FLOW RATE 1.0 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 10 µL	SAMPLE CONCENTRATION 1.0 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 8.3 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.4%	PASS
Identity (Method not recorded)	1024.2 ±2%	Obs: 1025.2 [M+H]+	PASS
Quantity found	95.0–105.0%	10.12 mg (101.2%)	PASS
Endotoxin	<1.0 EU/mg	<0.5 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Acetate salt form confirmed, high purity, light-protected.

crafa

CRAFA